Peroxisome proliferator-activated receptor-alpha and atherosclerosis: From basic mechanisms to clinical implications

Cardiology in Review

Volumn 13, Issue 5, 2005, Pages 240-246

  Israelian Konaraki, Zarmen ^a   Reaven, Peter D ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Fibric acids; Inflammation; PPAR

Indexed keywords

BEZAFIBRATE; CELL ADHESION MOLECULE; CYTOKINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEIN FUNCTION; REVIEW; RISK REDUCTION;

ACUTE-PHASE PROTEINS; ANIMALS; ATHEROSCLEROSIS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; LIGANDS; LIPID METABOLISM; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; PPAR ALPHA; RANDOMIZED CONTROLLED TRIALS; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; TREATMENT OUTCOME;

EID: 23944451559     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000137255.54390.12     Document Type: Review

References (25)

1. Marx M, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001;8:203-210.
2. Neve B, Fruchart J, Staels B. Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 2000;60:1245-1250.
3. Staels B. The PPAR system and regulation of lipoprotein metabolism. In: Betteridge, ed. Lipids and Vascular Disease-Current Issues, Martin Dunitz Ltd; 2001:27-37.
4. Ziouzenkova O, Perry S, Asatryan L, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA. 2003;100:2730-2735.
5. Fruchart J, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Current Atheroscler Rep. 2001;3:83-92.
6. Sun Z, Andersson R. NF-κB Activation and inhibition: a review. Shock. 2002;18:99-106.
7. Karin M, Chang L. AP-1-Glucocorticoid receptor crosstalk taken to higher level. J Endocrinol. 2001;169:447-451.
8. Adcock IM. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis. 1997;52:178-186.
9. Kleeman R, Gervois PP, Verschuren L, et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood. 2003;101:545-551.
10. Blake G, Ridker P. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
11. Gervois PP, Vu-Dac N, Kleeman R, et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem. 2001;276:33471-33477.
12. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferator-activated receptor activation inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Risk. 2000;40:822-831.
13. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol. 2001;12:511-518.
14. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation. 2001; 103:2531-2534.
15. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not PPAR-γ activators. Nature. 1998;25:790-793.
16. Duez H, Fruchart J, Staels B, PPAR's in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk. 2001;8:184-194.
17. Neve BP, Corseaux D, Chinetti G, et al. PPAR-α agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;16:207-219.
18. Marx N, Sukhova G, Collins T, et al. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
19. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes. Circ Res. 2002;90:703-710.
20. Rubin HB, Robins SJ, Collins D, et al. for VA-HIT Study Group. Diabetic, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs. High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med, 2002;162:2597-2604.
21. Robins SJ, Rubin HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26:1513-1517.
22. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995;92:1779-1785.
23. Steiner G, et al. (Diabetes Atherosclerosis Intervention Study Investigators). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet. 2001;357:905-910.
24. The BIP Study Group, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study, Circulation, 2000;102:21-27.
25. Ruotolo G, Ericsson CG, Tettamneti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.